EZH2 and diffuse large B-cell lymphoma: EPZ011989 is another selective and orally bioavailable EZH2 inhibitor that equipotently inhibits EZH2WT or EZH2MUT with an inhibition constant (Ki) of <3 nM and with the capacity to significantly inhibit DLBCL tumor growth in mouse xenografts [191].